Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The quinoline-5,8 dicarboxylic acid scaffold has been identified by a fragment-based approach as new potential lead compound for the development of JMJD3 inhibitors. Among them, 3-(2,4-dimethoxypyrimidin-5-yl)quinoline-5,8-dicarboxylic acid (compound 3) shows low micromolar inhibitory activity against Jumonji domain-containing protein 3 (JMJD3). The experimental evaluation of inhibitory activity against seven related isoforms of JMJD3 highlighted an unprecedented selectivity toward the biological target of interest.

Original publication

DOI

10.1002/cmdc.201800198

Type

Journal article

Journal

Chemmedchem

Publication Date

20/06/2018

Volume

13

Pages

1160 - 1164

Keywords

anticancer agents, drug discovery, fragment-based approach, molecular modeling, selective JMJD3 inhibitor, Binding Sites, Dicarboxylic Acids, Enzyme Inhibitors, Humans, Isoenzymes, Jumonji Domain-Containing Histone Demethylases, Molecular Docking Simulation, Molecular Dynamics Simulation, Quinolines